Selected research
Industry Research
Tuberculosis Vaccine Drug Industry Research Report 2026
Market perspective
The global Tuberculosis Vaccine Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Tuberculosis Vaccine Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Tuberculosis Vaccine Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Tuberculosis Vaccine Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Tuberculosis Vaccine Drug include Merck, Taj Pharmaceuticals, Serum Institute of India, Queen Saovabha Mem. Inst, Microgen, Japan BCG Lab, IVAC, GreenSignal Bio Pharma and China National Biotec, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Tuberculosis Vaccine Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Tuberculosis Vaccine Drug Market by Company
Merck
Taj Pharmaceuticals
Serum Institute of India
Queen Saovabha Mem. Inst
Microgen
Japan BCG Lab
IVAC
GreenSignal Bio Pharma
China National Biotec
Biomed Lublin
BioFarma
Ataulpho de Paiva
AJ Vaccines
Tuberculosis Vaccine Drug Segment by Type
Immune Vaccine
Therapy Vaccine
Tuberculosis Vaccine Drug Segment by Application
Self-Procurement
UNICEF
Other
Tuberculosis Vaccine Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tuberculosis Vaccine Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tuberculosis Vaccine Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tuberculosis Vaccine Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Tuberculosis Vaccine Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Tuberculosis Vaccine Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Tuberculosis Vaccine Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Immune Vaccine
- Therapy Vaccine
Applications
- Self-Procurement
- UNICEF
- Other
Companies covered
- Merck
- Taj Pharmaceuticals
- Serum Institute of India
- Queen Saovabha Mem. Inst
- Microgen
- Japan BCG Lab
- IVAC
- GreenSignal Bio Pharma
- China National Biotec
- Biomed Lublin
- BioFarma
- Ataulpho de Paiva
- AJ Vaccines
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Tuberculosis Vaccine Drug Market Size (2021-2032)
- 2.2.2 Global Tuberculosis Vaccine Drug Sales (2021-2032)
- 2.2.3 Global Tuberculosis Vaccine Drug Market Average Price (2021-2032)
- 2.3 Tuberculosis Vaccine Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Immune Vaccine
- 2.3.3 Therapy Vaccine
- 2.4 Tuberculosis Vaccine Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Self-Procurement
- 2.4.3 UNICEF
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Tuberculosis Vaccine Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Tuberculosis Vaccine Drug Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Tuberculosis Vaccine Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Tuberculosis Vaccine Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Tuberculosis Vaccine Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Tuberculosis Vaccine Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Tuberculosis Vaccine Drug, Product Type & Application
- 3.8 Global Manufacturers of Tuberculosis Vaccine Drug, Established Date
- 3.9 Global Tuberculosis Vaccine Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Merck
- 4.1.1 Merck Company Information
- 4.1.2 Merck Business Overview
- 4.1.3 Merck Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Merck Tuberculosis Vaccine Drug Product Portfolio
- 4.1.5 Merck Recent Developments
- 4.2 Taj Pharmaceuticals
- 4.2.1 Taj Pharmaceuticals Company Information
- 4.2.2 Taj Pharmaceuticals Business Overview
- 4.2.3 Taj Pharmaceuticals Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Taj Pharmaceuticals Tuberculosis Vaccine Drug Product Portfolio
- 4.2.5 Taj Pharmaceuticals Recent Developments
- 4.3 Serum Institute of India
- 4.3.1 Serum Institute of India Company Information
- 4.3.2 Serum Institute of India Business Overview
- 4.3.3 Serum Institute of India Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Serum Institute of India Tuberculosis Vaccine Drug Product Portfolio
- 4.3.5 Serum Institute of India Recent Developments
- 4.4 Queen Saovabha Mem. Inst
- 4.4.1 Queen Saovabha Mem. Inst Company Information
- 4.4.2 Queen Saovabha Mem. Inst Business Overview
- 4.4.3 Queen Saovabha Mem. Inst Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Queen Saovabha Mem. Inst Tuberculosis Vaccine Drug Product Portfolio
- 4.4.5 Queen Saovabha Mem. Inst Recent Developments
- 4.5 Microgen
- 4.5.1 Microgen Company Information
- 4.5.2 Microgen Business Overview
- 4.5.3 Microgen Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Microgen Tuberculosis Vaccine Drug Product Portfolio
- 4.5.5 Microgen Recent Developments
- 4.6 Japan BCG Lab
- 4.6.1 Japan BCG Lab Company Information
- 4.6.2 Japan BCG Lab Business Overview
- 4.6.3 Japan BCG Lab Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Japan BCG Lab Tuberculosis Vaccine Drug Product Portfolio
- 4.6.5 Japan BCG Lab Recent Developments
- 4.7 IVAC
- 4.7.1 IVAC Company Information
- 4.7.2 IVAC Business Overview
- 4.7.3 IVAC Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 IVAC Tuberculosis Vaccine Drug Product Portfolio
- 4.7.5 IVAC Recent Developments
- 4.8 GreenSignal Bio Pharma
- 4.8.1 GreenSignal Bio Pharma Company Information
- 4.8.2 GreenSignal Bio Pharma Business Overview
- 4.8.3 GreenSignal Bio Pharma Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 GreenSignal Bio Pharma Tuberculosis Vaccine Drug Product Portfolio
- 4.8.5 GreenSignal Bio Pharma Recent Developments
- 4.9 China National Biotec
- 4.9.1 China National Biotec Company Information
- 4.9.2 China National Biotec Business Overview
- 4.9.3 China National Biotec Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 China National Biotec Tuberculosis Vaccine Drug Product Portfolio
- 4.9.5 China National Biotec Recent Developments
- 4.10 Biomed Lublin
- 4.10.1 Biomed Lublin Company Information
- 4.10.2 Biomed Lublin Business Overview
- 4.10.3 Biomed Lublin Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Biomed Lublin Tuberculosis Vaccine Drug Product Portfolio
- 4.10.5 Biomed Lublin Recent Developments
- 4.11 BioFarma
- 4.11.1 BioFarma Company Information
- 4.11.2 BioFarma Business Overview
- 4.11.3 BioFarma Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 BioFarma Tuberculosis Vaccine Drug Product Portfolio
- 4.11.5 BioFarma Recent Developments
- 4.12 Ataulpho de Paiva
- 4.12.1 Ataulpho de Paiva Company Information
- 4.12.2 Ataulpho de Paiva Business Overview
- 4.12.3 Ataulpho de Paiva Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Ataulpho de Paiva Tuberculosis Vaccine Drug Product Portfolio
- 4.12.5 Ataulpho de Paiva Recent Developments
- 4.13 AJ Vaccines
- 4.13.1 AJ Vaccines Company Information
- 4.13.2 AJ Vaccines Business Overview
- 4.13.3 AJ Vaccines Tuberculosis Vaccine Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 AJ Vaccines Tuberculosis Vaccine Drug Product Portfolio
- 4.13.5 AJ Vaccines Recent Developments
5 Global Tuberculosis Vaccine Drug Market Scenario by Region
- 5.1 Global Tuberculosis Vaccine Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Tuberculosis Vaccine Drug Sales by Region: 2021-2032
- 5.2.1 Global Tuberculosis Vaccine Drug Sales by Region: 2021-2026
- 5.2.2 Global Tuberculosis Vaccine Drug Sales by Region: 2027-2032
- 5.3 Global Tuberculosis Vaccine Drug Revenue by Region: 2021-2032
- 5.3.1 Global Tuberculosis Vaccine Drug Revenue by Region: 2021-2026
- 5.3.2 Global Tuberculosis Vaccine Drug Revenue by Region: 2027-2032
- 5.4 North America Tuberculosis Vaccine Drug Market Facts & Figures by Country
- 5.4.1 North America Tuberculosis Vaccine Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Tuberculosis Vaccine Drug Sales by Country (2021-2032)
- 5.4.3 North America Tuberculosis Vaccine Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Tuberculosis Vaccine Drug Market Facts & Figures by Country
- 5.5.1 Europe Tuberculosis Vaccine Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Tuberculosis Vaccine Drug Sales by Country (2021-2032)
- 5.5.3 Europe Tuberculosis Vaccine Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Tuberculosis Vaccine Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Tuberculosis Vaccine Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Tuberculosis Vaccine Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Tuberculosis Vaccine Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Tuberculosis Vaccine Drug Market Facts & Figures by Country
- 5.7.1 South America Tuberculosis Vaccine Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Tuberculosis Vaccine Drug Sales by Country (2021-2032)
- 5.7.3 South America Tuberculosis Vaccine Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Tuberculosis Vaccine Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Tuberculosis Vaccine Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Tuberculosis Vaccine Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Tuberculosis Vaccine Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Tuberculosis Vaccine Drug Sales by Type (2021-2032)
- 6.1.1 Global Tuberculosis Vaccine Drug Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Tuberculosis Vaccine Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Tuberculosis Vaccine Drug Revenue by Type (2021-2032)
- 6.2.1 Global Tuberculosis Vaccine Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Tuberculosis Vaccine Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Tuberculosis Vaccine Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Tuberculosis Vaccine Drug Sales by Application (2021-2032)
- 7.1.1 Global Tuberculosis Vaccine Drug Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Tuberculosis Vaccine Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Tuberculosis Vaccine Drug Revenue by Application (2021-2032)
- 7.2.1 Global Tuberculosis Vaccine Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Tuberculosis Vaccine Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Tuberculosis Vaccine Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Tuberculosis Vaccine Drug Value Chain Analysis
- 8.1.1 Tuberculosis Vaccine Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Tuberculosis Vaccine Drug Production Mode & Process
- 8.2 Tuberculosis Vaccine Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Tuberculosis Vaccine Drug Distributors
- 8.2.3 Tuberculosis Vaccine Drug Customers
9 Global Tuberculosis Vaccine Drug Analyzing Market Dynamics
- 9.1 Tuberculosis Vaccine Drug Industry Trends
- 9.2 Tuberculosis Vaccine Drug Industry Drivers
- 9.3 Tuberculosis Vaccine Drug Industry Opportunities and Challenges
- 9.4 Tuberculosis Vaccine Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst